Evidence map›Paper›PMID 41801896›Full record

ArticlePLoS neglected tropical diseases2026

Functionally-derivatized Nanoantibodies as novel tools for Giardia lamblia cyst detection.

Corina D Wirdnam, Timothé Schaerer, Matthias Rubin, Alexander Oberli, Saša Štefanić, Adrian B Hehl, Carmen Faso

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Corina D WirdnamInstitute of Cell Biology, University of Bern, Bern, Switzerland.
Timothé SchaererInstitute of Cell Biology, University of Bern, Bern, Switzerland.
Matthias RubinInstitute for Infectious Diseases, University of Bern, Bern, Switzerland.
Alexander OberliInstitute for Infectious Diseases, University of Bern, Bern, Switzerland.
Saša ŠtefanićNanoantibody Service Facility, University of Zurich, Zurich, Switzerland.
Adrian B HehlNanoantibody Service Facility, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-2110-4445
Carmen FasoInstitute of Cell Biology, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0002-1831-9365

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Giardia lamblia (syn. intestinalis, duodenalis) is the causative agent of Giardiasis, a diarrheal disease of global medical importance, especially problematic in young children living in unhygienic, resource-constrained settings. Diagnostics of potential Giardia infections are generally done through classic light-microscopy stool examination. This is often insufficient, and ELISA-based fluorescence detection using costly proprietary reagents is employed. These reagents are often not affordable in contexts where they are needed the most, and this limits their use to resource-rich settings where Giardiasis is rarely problematic. To address these issues in medical equity while designing novel strategies to investigate the Giardia cyst wall, we report on the development and characterisation of alpaca derived single-domain antibodies, known as nanoantibodies, elicited against G. lamblia enriched cyst-wall preparations. We evaluated the effectiveness and binding capacity of twelve unique E. coli-produced recombinant nanoantibody sequences for Giardia cyst wall detection and provide proof of concept for the effectiveness and versatility of these protein domains.

Indexed as

Antibodies, ProtozoanGiardia lambliaGiardiasisSingle-Domain AntibodiesAnimalsAntigens, ProtozoanCamelids, New WorldEnzyme-Linked Immunosorbent AssayEscherichia coliHumansAntibodies, ProtozoanAntigens, ProtozoanSingle-Domain Antibodies

Identifiers

PMID41801896
PMCPMC12970868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.